SEC Filing Summary: Synta Pharmaceuticals Corp. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Synta Pharmaceuticals Corp. on March 31, 2015. The filing discloses the entry into a material definitive agreement regarding a public offering of common stock. Note: The request metadata referenced "Madrigal Pharmaceuticals," but the filing text explicitly identifies the registrant as Synta Pharmaceuticals Corp.
Key Financial Metrics and Transaction Details
- Transaction Type: Public offering of common stock.
- Shares Offered: 22,000,000 shares at a public offering price of $1.75 per share.
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to an additional 3,300,000 shares.
- Expected Gross Proceeds: Approximately $38.5 million (excluding underwriting discounts, commissions, and expenses, and assuming no exercise of the over-allotment option).
- Expected Closing Date: On or about April 6, 2015.
- Underwriters: Jefferies LLC and Cowen and Company, LLC.
Material Changes and Director Participation
The filing details significant participation by the Company's directors in the offering, with an aggregate allocation of 7,257,142 shares:
- Bruce Kovner: Purchasing 6,857,142 shares through an affiliated entity. His beneficial ownership will increase from approximately 27.7% to 28.3% post-offering.
- Wyandanch Partners, L.P. (controlled by Director Keith R. Gollust): Purchasing 350,000 shares. Mr. Gollust's beneficial ownership will decrease from approximately 3.1% to 2.8% post-offering.
- Robert Wilson: Purchasing 50,000 shares. His beneficial ownership will remain less than 1% post-offering.
Guidance, Outlook, and Risks
The filing does not provide specific financial guidance, revenue outlook, or management commentary regarding operational performance. The document includes standard legal disclaimers stating that representations and warranties in the Underwriting Agreement are for the benefit of the contracting parties and should not be relied upon by investors as characterizations of the Company's actual state of facts. The closing of the offering is subject to the satisfaction of customary closing conditions.
Investor Verification Checklist
- Verify the final closing date and actual net proceeds after deducting underwriting discounts and expenses.
- Confirm whether the underwriters exercised the 3,300,000 share over-allotment option.
- Review the press release (Exhibit 99.1) for any additional context on the use of proceeds.
- Check subsequent filings for the updated capitalization table reflecting the new share count.